Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Sym015: MET antibody mixture for advanced solid tumors

Ross Camidge • 28 Sep 2019
ESMO 2019
General Lung Cancer Antibodies Sym015

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase 1a/2a trial of Sym015, a MET antibody mixture, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Ross Camidge

3:21
Hot topics in 2020: lung cancer
Ross Camidge • 26 Mar 2020
4:15
COVID-19 & treating patients with lung cancer
Ross Camidge • 26 Mar 2020
10:43
Updates in ALK+ NSCLC
Ross Camidge • 26 Mar 2020
1:30
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Ross Camidge • 28 Sep 2019

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals